2023

• business2023/09/26

  Notice of Termination of License Agreement for AAT-007 & AAT-008 (EP4 Antagonist) for Global Immunooncology

  AskAt Inc. (Headquarters: Nagoya, Japan; President: Akihiro Furuta; hereinafter referred to as "AskAt") announced today the termination of a license agreement for AAT-007 & AAT-008 (EP4 Antagonist) for global immuno-oncology as of March 20, 2024, which was originally signed with Ikena Oncology Inc (Headquarters: Massachusetts, USA; hereinafter referred to as "Ikena") on December 14, 2017.

• patent2023/08/30

  Canadian Intellectual Property Office (CIPO) Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received a Notice of Allowance dated August 21, 2023 from the Canadian Intellectual Property Office (CIPO) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids.

• company2023/08/25

  AskAt to be featured on Nagoya TV's "Success" (2023/9/2 7:55~)

  AskAt President & CEO Akihiro Furuta will be interviewed on “Success,” a TV program broadcast in the Tokai region focusing on entrepreneurs currently attracting attention in these three prefectures. The program introduces their passion, true faces, and success stories by delving into the secrets behind their corporate success. All of AskAt’s employees will appear on the program.
  

• patent2023/08/19

  IP Australia Grants AskAt a Patent for the AAT-730 Salt & Crystal Forms

  AskAt received a Patent Registration Certificate dated July 27, 2023 from IP Australia for a salt and crystal forms patent for the company’s CB2 agonist, AAT-730. The certificate was issued in connection with Australian Patent Application No. 2021380315 (Filing Date: November 11, 2021).

• business2023/07/27

  Oxford Cannabinoid Technologies starts a First-In-Human Clinical Trial for Cannabinoid CB2 Receptor Agonist AAT-730 in the United Kingdom

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO: Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced an initiation of Phase 1 clinical trial for AAT-730, in which AAT-730 will be firstly administered to human (First-In-Human, FIH), in the United Kingdom.

• company2023/06/29

  AskAt Launches “AskAt Advisory Services" to Bridge Japanese Founders and Global Investors

  AskAt Inc. (Headquarters: Nagoya, Japan) today announced the launch of a new service, “AskAt Advisory Services” (AAS) to connect Japanese founders and global investors for new business growth opportunities.

• business2023/06/28

• patent2023/06/19

  Korean Intellectual Property Office Grants Expansion of AskAt’s EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease

  AskAt received a Notice of Allowance dated June 8, 2023 from the Korean Intellectual Property Office (KIPO) for an EP4 receptor antagonist use patent in the treatment of cartilage disease.

• patent2023/06/05

  European Patent Office Grants Expansion of AskAt’s EP4 Receptor Antagonist Use Patent for the Treatment of Cancer

  AskAt received a communication under Rule 71(3) EPC dated May 19, 2023
  from the European Patent Office, with which the grant of the European patent is proposed. This grant of European Patent Application No. 18191714.7 is an EP4 receptor antagonist use patent for the treatment of cancer, particularly for the use of grapiprant in the treatment of epithelial cancer

• business2023/05/19

  Oxford Cannabinoid Technologies to Initiate First-In-Human Clinical Trial for Cannabinoid CB2 Receptor Agonist AAT-730 in the United Kingdom

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO：Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Wales Research Ethics Committee 2 (REC 2) have approved the combined Phase I clinical trial application for AAT-730 (OCT461201).

• patent2023/05/15

  Korean Intellectual Property Office Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received a Notice of Allowance dated May 1, 2023 from the Korean
  Intellectual Property Office (KIPO) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Korean Patent Application No. 10-2021-7026299 (Filing Date: January 20, 2020).

• patent2023/04/17

  Mexican Patent and Trademark Office Grants AskAt an AAT-076 Production Process Patent

  AskAt received a Notice of Allowance for a Mexican patent dated April 11, 2023 from the National Institute of Indigenous Peoples (Instituto Nacional de los Pueblos Indígenas, INPI). The patent covers a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Application Number MX/a/2021/008612 (Filing Date: January 20, 2020).

• ir2023/03/31

  10th period financial statement release

  10th period financial statement release

• patent2023/02/10

  Rospatent Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received an Official Decision of Grant dated February 1, 2023 from the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Russian Patent Application No. 2021124682 (Filing Date: January 20, 2020).

• business2023/01/11

  Combined Clinical Trial Application of Cannabinoid CB2 Receptor Agonist AAT-730 for First-In-Human Clinical Trial has been submitted by Oxford Cannabinoid Technologies to UK Regulatory Agencies

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO：Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that a combined clinical trial application for AAT-730 (OCT461201) has been successfully submitted to UK Medicines & Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) on January 4th, 2023.

• science2023/01/11

  Ikena Oncology presented results of a clinical trial of grapiprant (AAT-007/IK-007) in patients with advanced microsatellite stable colorectal cancer

  Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.

• patent2023/01/06

  European Patent Office Grants AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease

  AskAt received a notice of the decision to grant a European patent pursuant to Article 97(1) EPC from the European Patent Office as of December 8, 2022. This grant of European Patent Application No. 14768803.0 (Filing Date: March 19, 2014), is an EP4 receptor antagonist use patent for the treatment of cartilage disease.